Ajax Therapeutics Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 9

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $2.3B

Ajax Therapeutics General Information

Description

Developer of targeted therapy drugs designed for the treatment of hematologic cancers. The company utilizes molecular genetics and biology to develop new classes of therapies that are selective for specific drug targets, while aiming to minimize interactions with related proteins, enabling healthcare providers to access effective and precise treatment options for patients with blood cancers.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • 275 Madison Avenue
  • 39th Floor
  • New York, NY 10016
  • United States
+1 (917)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Parent Company
Vertical(s)
Corporate Office
  • 275 Madison Avenue
  • 39th Floor
  • New York, NY 10016
  • United States
+1 (917)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Ajax Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Merger/Acquisition 13-Jun-2026 $2.3B Completed Clinical Trials - Phase 1
4. Secondary Transaction - Private Completed Clinical Trials - Phase 1
3. Later Stage VC (Series C) 13-May-2024 Completed Clinical Trials - Phase 1
2. Early Stage VC (Series B) 01-Jun-2021 $40M $48M Completed Clinical Trials - Phase 1
1. Early Stage VC (Series A) 28-Jun-2019 $8M $8M Completed Clinical Trials - Phase 1
To view Ajax Therapeutics’s complete valuation and funding history, request access »

Ajax Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C
Series B
Series A 8,000,000 $0.000100 $1 $1 1x $1 8.8%
To view Ajax Therapeutics’s complete cap table history, request access »

Ajax Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of targeted therapy drugs designed for the treatment of hematologic cancers. The company utilizes molecular ge
Drug Discovery
New York, NY
9 As of 2024

Seattle, WA
 

Boston, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Ajax Therapeutics Competitors (3)

One of Ajax Therapeutics’s 3 competitors is CTI BioPharma, a Formerly VC-backed company based in Seattle, WA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CTI BioPharma Formerly VC-backed Seattle, WA
Vor Biopharma Formerly VC-backed Boston, MA
Cornerstone Pharmaceuticals Venture Capital-Backed Cranbury, NJ
You’re viewing 3 of 3 competitors. Get the full list »

Ajax Therapeutics Patents

Ajax Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260078131-A1 Pyrrolo-pyridazine inhibitors of jak2 Pending 27-Jun-2025
WO-2026078542-A1 Janus kinase 2 degraders Pending 07-Oct-2024
WO-2026055409-A1 Pyrrolo-pyridazine inhibitors of jak2 Pending 06-Sep-2024
WO-2025245175-A1 Macrocyclic heteroaromatic inhibitors of jak2 Pending 22-May-2024
AU-2025265863-A1 5,6 bicyclic heteroaromatic inhibitors of jak2 Pending 29-Apr-2024 A61P35/00
To view Ajax Therapeutics’s complete patent history, request access »

Ajax Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ajax Therapeutics Former Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
Boxer Capital Corporate Venture Capital Minority
EcoR1 Capital Venture Capital Minority
Goldman Sachs Asset Management Asset Manager Minority
Inning One Ventures Venture Capital Minority
Memorial Sloan Kettering Cancer Center Accelerator/Incubator Minority
You’re viewing 5 of 11 investors. Get the full list »

Ajax Therapeutics FAQs

  • When was Ajax Therapeutics founded?

    Ajax Therapeutics was founded in 2019.

  • Where is Ajax Therapeutics headquartered?

    Ajax Therapeutics is headquartered in New York, NY.

  • What is the size of Ajax Therapeutics?

    Ajax Therapeutics has 9 total employees.

  • What industry is Ajax Therapeutics in?

    Ajax Therapeutics’s primary industry is Drug Discovery.

  • Is Ajax Therapeutics a private or public company?

    Ajax Therapeutics is a Private company.

  • What is the current valuation of Ajax Therapeutics?

    The current valuation of Ajax Therapeutics is .

  • What is Ajax Therapeutics’s current revenue?

    The current revenue for Ajax Therapeutics is .

  • How much funding has Ajax Therapeutics raised over time?

    Ajax Therapeutics has raised $143M.

  • Who are Ajax Therapeutics’s investors?

    Boxer Capital, EcoR1 Capital, Goldman Sachs Asset Management, Inning One Ventures, and Memorial Sloan Kettering Cancer Center are 5 of 11 investors who have invested in Ajax Therapeutics.

  • Who are Ajax Therapeutics’s competitors?

    CTI BioPharma, Vor Biopharma, and Cornerstone Pharmaceuticals are competitors of Ajax Therapeutics.

  • When was Ajax Therapeutics acquired?

    Ajax Therapeutics was acquired on 13-Jun-2026.

  • Who acquired Ajax Therapeutics?

    Ajax Therapeutics was acquired by Lilly USA.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process